NVO·Healthcare·Pharma
Novo Nordisk Hims partnership Boom: GLP‑1 market power shift
Can the Novo Nordisk Hims partnership turn a legal fight over compounded GLP‑1s into a powerful new growth channel for…
Pharma
NVO·Healthcare·Pharma
LLY·Healthcare·Pharma
Eli Lilly Investment -$37.70: Rally Warning for Bulls
Can the latest Eli Lilly Investment wave in GLP-1 plants and AI supercomputing still justify a trillion-dollar style valuation? How…
NVO·Healthcare·Pharma
Novo Nordisk Price War: -2.6% Stock Pressure After CagriSema Shock
Novo Nordisk price war, CagriSema shock, and stock plunge: How hard does the GLP-1 double blow hit the market leader…
NVO·Healthcare·Pharma
Novo Nordisk CagriSema -2.6%: Pipeline Shock and Price War
Novo Nordisk CagriSema flops in Phase 3, stock -2.6%: What does the study shock and price war for Wegovy and…
LLY·Healthcare·Pharma
Eli Lilly Weight Loss +5.2%: Rally Following Study Shock at Novo Nordisk
Eli Lilly Weight Loss: Stock jumps after weaker CagriSema data from Novo Nordisk – what does the rally mean for…
NVO·Healthcare·Pharma
Novo Nordisk CagriSema -15%: Study Shock Causes Stock Plunge
Novo Nordisk CagriSema misses against Tirzepatide in REDEFINE-4; stock plunges 15% in pre-market – what this means for investors.